CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	347.56	298.26	389.48	211.89	923.03
Short-Term Investments	1,628	1,606	1,304	1,603	1,456
Cash & Short-Term Investments	1,976	1,904	1,694	1,815	2,379
Cash Growth	3.78%	12.41%	-6.70%	-23.70%	40.75%
Accounts Receivable	-	25	200	-	0.31
Other Receivables	-	-	6.5	11.2	8.4
Receivables	-	25	206.5	11.2	8.71
Prepaid Expenses	5.95	8.31	7.89	26.01	29.68
Restricted Cash	3.89	-	-	0.5	-
Total Current Assets	1,986	1,937	1,908	1,853	2,418
Property, Plant & Equipment	247.58	277.55	305.94	320.56	312.04
Long-Term Investments	22.6	12.9	1.97	53.13	-
Other Intangible Assets	-	-	0.02	0.07	0.13
Other Long-Term Assets	9.4	14.45	13.57	16.28	22.2
Total Assets	2,265	2,242	2,230	2,243	2,752
Accounts Payable	11.14	14.71	38.15	27.43	14.82
Accrued Expenses	34.46	39.56	40.67	61.33	77.77
Current Portion of Leases	18.58	17.29	15.63	15.84	12.16
Current Income Taxes Payable	1.11	0.45	0.44	0.14	0.72
Current Unearned Revenue	15.77	3.85	4.11	-	1.01
Other Current Liabilities	68.06	11.93	9.81	16.38	13.4
Total Current Liabilities	149.12	87.78	108.79	121.11	119.88
Long-Term Leases	188.17	206.41	223.01	228.18	212.87
Long-Term Unearned Revenue	-	12.32	14.01	12.32	12.32
Other Long-Term Liabilities	6.14	3.44	0.96	5.97	7.34
Total Liabilities	343.43	309.95	346.77	367.58	352.42
Common Stock	3.09	2.7	2.5	2.44	2.39
Additional Paid-In Capital	3,862	3,294	2,878	2,735	2,598
Retained Earnings	-1,948	-1,366	-999.7	-846.09	-195.92
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	4.82	1.84	1.91	-15.65	-5.07
Total Common Equity	1,922	1,932	1,883	1,875	2,399
Shareholders' Equity	1,922	1,932	1,883	1,875	2,399
Total Liabilities & Equity	2,265	2,242	2,230	2,243	2,752
Total Debt	206.75	223.69	238.63	244.02	225.03
Net Cash (Debt)	1,769	1,680	1,457	1,624	2,154
Net Cash Growth	5.29%	15.31%	-10.30%	-24.59%	32.24%
Net Cash Per Share	19.67	19.92	18.39	20.89	26.79
Filing Date Shares Outstanding	95.99	85.77	80.28	78.65	77.07
Total Common Shares Outstanding	95.89	85.74	80.04	78.51	76.99
Working Capital	1,837	1,849	1,799	1,732	2,298
Book Value Per Share	20.04	22.53	23.52	23.89	31.17
Tangible Book Value	1,922	1,932	1,883	1,875	2,399
Tangible Book Value Per Share	20.04	22.53	23.52	23.89	31.16
Machinery	56.28	54.4	53.26	49.62	36.25
Construction In Progress	3.96	6.12	8.86	6.16	52.4
Leasehold Improvements	146.67	145.85	143.26	141.68	86.74

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q